Relaxin H2 (human) trifluoroacetate salt
Modify Date: 2025-08-21 10:31:51
Relaxin H2 (human) trifluoroacetate salt structure
|
Common Name | Relaxin H2 (human) trifluoroacetate salt | ||
|---|---|---|---|---|
| CAS Number | 99489-94-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Relaxin H2 (human) trifluoroacetate saltSerelaxin (RLX-030), a recombinant form of human gene-2 relaxin targeting the RLN receptor, is a vasoactive peptide hormone with an antifibrotic activity[1][2][3]. |
| Name | Serelaxin |
|---|
| Description | Serelaxin (RLX-030), a recombinant form of human gene-2 relaxin targeting the RLN receptor, is a vasoactive peptide hormone with an antifibrotic activity[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vivo | Serelaxin (0.5 mg/kg per day, subcutaneous administration) produces 20 to 40 ng/mL of circulating hormone, which successfully prevents and reduces fibrosis progression in various experimental models of injury. The doses do not exhibit significant toxicity[1]. Serelaxin restores endothelial function by increasing nitric oxide (NO)-mediated relaxation but not endothelium-derived hyperpolarisation (EDH)[2]. Animal Model: Six- to 8-week-old male mice (on a 129sv or 129sv×C57B6J background, which were equally sensitive to tissue injury and fibrosis)[1]. Dosage: 0.5 mg/kg. Administration: Subcutaneous administration per day for 7 days. Result: Produced 20 to 40 ng/mL of circulating hormone. |
| References |
[3]. Serelaxin. |
| No Any Chemical & Physical Properties |